Arecor Therapeutics plc (AIM:AREC)

Market Cap	15.86M
Revenue (ttm)	5.05M
Net Income (ttm)	-10.24M
Shares Out	37.76M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,454
Average Volume	31,564
Open	40.77
Previous Close	42.00
Day's Range	40.35 - 42.00
52-Week Range	0.55 - 170.00
Beta	-0.40
RSI	59.37
Earnings Date	Apr 17, 2025

About Arecor Therapeutics

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 50
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AREC

Financial Performance

In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.